期刊
NEUROLOGY
卷 77, 期 22, 页码 1965-1971出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31823a0c7f
关键词
-
资金
- NICHD [P0I-HD32062]
- CTSA [1-ULI-RR024156]
- Irving Research Scholar Award
- Marriott Mitochondrial Disorder Clinical Research Fund
- Colleen Giblin Foundation
- Santhera Pharmaceuticals
- Penwest Pharmaceuticals Co.
- PTC Therapeutics, Inc.
- NIH/NINDS
- US Department of Defense
- SMA Foundation
- Canadian Institutes of Health Research
- UCB
- NIH/NINDS Neurological Science Academic Development
- Spinal Muscular Atrophy Foundation
- American Academy of Neurology Foundation
- NIH (NIA/NCRR)
- American College of Medical Genetics
- Edison Pharmaceuticals, Inc.
- NIH
- Muscular Dystrophy Association USA
- Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF)
- Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRE)
- NIH (NINDS, NICHD)
- Will Foundation
- Pediatric Neurotransmitter Disease Association
Objective: To describe the natural history of clinical and laboratory features associated with the m.3243A>G mitochondrial DNA point mutation. Natural history data are needed to obtain prognostic information and for clinical trial planning. Methods: We included 85 matrilineal relatives from 35 families with at least 2 visits in this prospective cohort study. Thirty-one were fully symptomatic with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and 54 were carrier relatives. Evaluations included standardized questionnaires (medical history and daily living functioning), physical examination, neuropsychological testing, and a battery of imaging and laboratory tests. We evaluated changes in clinical and laboratory features over time and survival. Outcomes are reported over a follow-up period of up to 10.6 years (mean 3.8 +/- 2.2 years for patients and 5.5 +/- 3.0 for carrier relatives). Results: Neurologic examination, neuropsychological testing, and daily living scores significantly declined in all patients with MELAS, whereas no significant deterioration occurred in carrier relatives. Cerebral MRI scores declined significantly in patients with MELAS. Magnetic resonance spectroscopy estimates of lactate in the lateral ventricles increased over time, and high lactate was associated with increased mortality. Symptom onset in childhood often was associated with worse outcome. Patients with MELAS had a greater death rate than carrier relatives. Conclusions: Patients with MELAS carrying the m.3243A>G mutation show a measurable decline in clinical and imaging outcomes. It is hoped that these data will be helpful in anticipating the disease course and in planning clinical trials for MELAS. Neurology (R) 2011;77:1965-1971
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据